Literature DB >> 23388475

Concentrations and activities of metalloproteinases 2 and 9 and their inhibitors (TIMPS) in chronic pancreatitis and pancreatic adenocarcinoma.

A Lekstan1, P Lampe, J Lewin-Kowalik, M Olakowski, B Jablonska, K Labuzek, H Jedrzejowska-Szypulka, E Olakowska, D Gorka, I Filip, D Dranka-Bojarowska.   

Abstract

UNLABELLED: Pancreatic cancer (PC) and chronic pancreatitis (CP) are still significant problems. The aim of this study was a comparative analysis of the activity and concentrations of matrix metalloproteinases 2 and 9 and the concentrations of their tissue inhibitors (TIMP 1 and 2) in the PC compared to CP tissue homogenates. The study was performed in a group of 63 patients with pancreatic cancer or chronic pancreatitis selected for resection procedures. Group 1 consisted of 31 patients with CP, group 2 consisted of 32 patients with PC. There was no coincidence of pancreatic cancer in CP group. The pancreatic tumor samples have been properly prepared in order to perform electrophoresis and immunoassay testing. The activity of MMPs and the concentrations of MMPs and TIMPs were evaluated.
RESULTS: the revealed activities of gelatinases and concentrations levels of the gelatinases and their inhibitors were significantly higher in the PC tissue samples compared to CP. In both groups, higher concentrations of MMP9 compared to MMP2 and TIMP2 compared to TIMP1 were shown. High potential for tumor invasiveness demonstrated by the formation of lymph node metastases was characterized by the higher concentrations of MMP9 and TIMP2. However, in the case of infiltration of the nerve fibers, a decrease in the concentration of MMP2 was found.
CONCLUSIONS: gelatinases and their inhibitors play important role in the pathogenesis of the CP as well as PC. The activity and concentration of gelatinases and the concentration of their inhibitors were all significantly higher in the PC group.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23388475

Source DB:  PubMed          Journal:  J Physiol Pharmacol        ISSN: 0867-5910            Impact factor:   3.011


  15 in total

1.  The protective effect of betacellulin against acute pancreatitis is ERBB4 dependent.

Authors:  Kathrin Hedegger; Franziska Stumpf; Helmut Blum; Alexander Graf; Roland Michael Schmid; Marina Lesina; Hana Algül; Marlon Roberto Schneider; Maik Dahlhoff
Journal:  J Gastroenterol       Date:  2019-08-27       Impact factor: 7.527

Review 2.  Process of hepatic metastasis from pancreatic cancer: biology with clinical significance.

Authors:  Haojun Shi; Ji Li; Deliang Fu
Journal:  J Cancer Res Clin Oncol       Date:  2015-08-07       Impact factor: 4.553

3.  Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study.

Authors:  Johanna Bendell; Sunil Sharma; Manish R Patel; Kevin S Windsor; Zev A Wainberg; Michael Gordon; Jorge Chaves; Jordan Berlin; Carrie Baker Brachmann; Marianna Zavodovskaya; JieJane Liu; Dung Thai; Pankaj Bhargava; Manish A Shah; Saad A Khan; Alexander Starodub
Journal:  Oncologist       Date:  2020-09-17

4.  Association of Matrix Metalloproteinase-7 Genotypes with the Risk of Bladder Cancer.

Authors:  Cheng-Hsi Liao; Wen-Shin Chang; Chia-Wen Tsai; Pei-Shin Hu; Hsi-Chin Wu; Shih-Wei Hsu; Guan-Liang Chen; Te-Cheng Yueh; Te-Chun Shen; Te-Chun Hsia; DA-Tian Bau
Journal:  In Vivo       Date:  2018 Sep-Oct       Impact factor: 2.155

5.  Powerful inhibition of experimental human pancreatic cancers by receptor targeted cytotoxic LH-RH analog AEZS-108.

Authors:  Karoly Szepeshazi; Andrew V Schally; Norman L Block; Gabor Halmos; Mehrdad Nadji; Luca Szalontay; Irving Vidaurre; Andrew Abi-Chaker; Ferenc G Rick
Journal:  Oncotarget       Date:  2013-05

Review 6.  Neutrophil-Derived Proteases in the Microenvironment of Pancreatic Cancer -Active Players in Tumor Progression.

Authors:  Klaus Felix; Matthias M Gaida
Journal:  Int J Biol Sci       Date:  2016-01-28       Impact factor: 6.580

7.  The co-expression of MMP-9 and Tenascin-C is significantly associated with the progression and prognosis of pancreatic cancer.

Authors:  Yingqiang Xu; Zhonghu Li; Peng Jiang; Guo Wu; Kai Chen; Xi Zhang; Xiaowu Li
Journal:  Diagn Pathol       Date:  2015-12-10       Impact factor: 2.644

Review 8.  mTOR: An attractive therapeutic target for osteosarcoma?

Authors:  Liu Ding; Liu Congwei; Qing Bei; Yang Tao; Wang Ruiguo; Yu Heze; Dou Bo; Li Zhihong
Journal:  Oncotarget       Date:  2016-08-02

9.  Anti-metastasis effect of fucoidan from Undaria pinnatifida sporophylls in mouse hepatocarcinoma Hca-F cells.

Authors:  Peisheng Wang; Zhichao Liu; Xianli Liu; Hongming Teng; Cuili Zhang; Lin Hou; Xiangyang Zou
Journal:  PLoS One       Date:  2014-08-27       Impact factor: 3.240

10.  Expressions of Matrix Metalloproteinases 2, 7, and 9 in Carcinogenesis of Pancreatic Ductal Adenocarcinoma.

Authors:  Katarzyna Jakubowska; Anna Pryczynicz; Joanna Januszewska; Iwona Sidorkiewicz; Andrzej Kemona; Andrzej Niewiński; Łukasz Lewczuk; Bogusław Kędra; Katarzyna Guzińska-Ustymowicz
Journal:  Dis Markers       Date:  2016-06-26       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.